Drugs / IM83 CAR-T Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06412458 | Jun 2024 → Jun 2025 | bone osteosarcoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05123209 | Aug 2021 → Aug 2023 | liver cancer | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM83 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06412458 ↗ |
| Modality | Cell therapy | “IM83 CAR-T cells” NCT05123209 ↗ |